Oniria Therapeutics

Oniria Therapeutics is a biotech startup founded in 2021 with a focus on revolutionizing cancer treatment through precision oncology. The company, based in Spain, has garnered attention for its cutting-edge approach to developing first-in-class drugs in the field of oncology. A recent milestone for Oniria Therapeutics was the successful closure of a €1.28M Seed Round of investment on 11 May 2023. The funding was secured from a diverse group of investors including BStartup, Investigo, Torres Quevedo, Fundacion Botin, Startup Capital Ventures, and ACCIÓ. This financial boost is expected to propel the company's innovative therapies forward. Oniria Therapeutics' flagship product, which allosterically activates TET2, a master epigenetic enzyme, demonstrates its commitment to developing novel targeted strategies to overcome the persistence of dormant tumor cells. As a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB), and the Catalan Institution for Research and Advanced Studies (ICREA), Oniria Therapeutics has strong roots in renowned research institutions, bolstering its credibility and potential for groundbreaking advancements in cancer treatment. The company's slogan, "A shift in cancer treatment methodology makes a world of difference," encapsulates its mission to bring about transformative change in the field of oncology. With the recent investment and its promising approach to precision oncology, Oniria Therapeutics is poised to make a significant impact in the biopharma and biotechnology industries.